Circio: circRNA poster to be presented at the 15th international adenovirus meeting

Oslo, Norway, 25 September 2023 – Circio Holding ASA (OSE: CRNA) today announces that an abstract describing its circular RNA platform has been accepted for poster presentation at the 15th international adenovirus meeting in Brac Island, Crotia.

The abstract describes the development of Circio’s proprietary circAde vector system for therapeutic protein expression. The abstract describes the development of Circio’s proprietary circVec vector system for therapeutic protein expression. Key elements necessary for circRNA biogenesis were systematically screened and optimized to facilitate high yield circRNA expression. Additionally, we describe the development of circVac and circAde vector systems for vaccine and cancer immunotherapy platforms, respectively.  Here, we show the importance of vector design for durable circRNA expression and functionality of our viral vector, circAde. Our results highlight the potential of the circVec platform for the development of novel, more effective strategies for the treatment of diseases in which durable transgene expression is desirable.

The poster is scheduled for presentation today, 25 September 2023, and will be available on Circio’s website after the presentation.

Poster title: circAde, a viral vector system for high and durable protein expression
Date and time: Monday 25 September 2023, 20:00- 21:30 CEST
Location: Brač Island, Croatia
Abstract number: 16
Presenter: Eoghan O’Leary, Director RNA Research

About The International Adenovirus Meeting

The International Adenovirus Meeting is the gathering point for scientists interested in all aspects of adenovirus infection. Internationally leading experts will share their ideas and latest results on adenovirus detection in nature; their clinical impact; their use as therapeutic vaccines and oncolytics; assembly and lifecycle; and interactions with host proteins, receptors and cells.

Exchange of ideas and information among scientists working in all fields of adenovirus biology and applications is fundamental to advancing our ability to fight against adenovirus-induced disease outbreaks, and to repurpose the virus as an efficient tool in biomedicine.

The International Adenovirus Meeting is the only conference worldwide focusing entirely on this particular virus family comprising all aspects of their biology, pathology and biotechnological applications.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for cancer, vaccines, rare disease, protein replacement therapy and cell therapy. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA that can be deployed for many purposes. The most advanced concept, circAde, builds on the company´s validated adenovirus platform to deliver circRNA for durable expression of therapeutic proteins directly into cancer cells. This unique approach is the only currently known circRNA program capable of targeting solid tumors. The circVec platform has broad potential applications, and Circio´s strategy is to generate one or more lead candidates for in house development in specific disease indications and in parallel seek partnerships for other technical applications and therapeutic areas. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.

In addition to Circio’s circRNA program, the Company’s’ clinical stage immunotherapy programs are designed to activate the patient´s own immune system to fight cancer cells and provide benefit to patients with no or few treatment alternatives. ONCOS-102 has demonstrated an excellent safety profile, strong immune responses and clinical efficacy in several cancer types in Phase 1/2 studies, both as monotherapy and in combinations with checkpoint inhibitors or standard-of-care chemotherapy. A phase 2 trial to confirm the therapeutic activity of ONCOS-102 in melanoma patients resistant to PD-1 checkpoint inhibitor treatment has been designed, and Circio is seeking external financing and/or partnerships to continue the clinical development.               

Circio’s second clinical stage program is an immunotherapy targeting KRAS driver mutations. TG01 has previously shown robust immune responses and encouraging clinical benefit in surgically resected pancreatic cancer and is currently being tested in two clinical trials in RAS-mutated pancreatic cancer and multiple myeloma in the USA and Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating broad future optionality for the TG01 program at low cost to Circio.